No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
CN Stock MarketDetailed Quotes
000999 China Resources Sanjiu Medical & Pharmaceutical
- 41.80
- +0.76+1.85%
Noon Break Mar 14 11:30 CST
53.68BMarket Cap15.94P/E (TTM)
41.94High41.07Low96.04KlotVolume41.07Open41.04Pre Close400.27MTurnover0.75%Turnover Ratio15.94P/E (Static)1.28BShares51.5552wk High2.70P/B53.32BFloat Cap35.2452wk Low45.14Limit Up1.28BShs Float51.55Historical High36.94Limit Down2.12%Amplitude-4.62Historical Low2.15Dividend TTM41.68Avg Price33.56KlotAsk5.15%Div YieldTTM100Lot Size56.76KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
China Resources Sanjiu Medical & Pharmaceutical (000999): All Business Sectors are growing steadily, expecting progress in mergers and acquisitions.
Performance review On March 12, 2025, the company released the 2024 annual report. In 2024, the company achieved a revenue of 27.617 billion yuan (up 11.63% year-on-year), with a net income of 3.368 billion yuan (
CR Sanjiu Logs 18% Boost in 2024 Profit
China Resources 39:2024 Annual Report Summary
China Resources 39:2024 Annual Report
CHINARES PHARMA (03320): China Resources Sanjiu Medical & Pharmaceutical's net profit attributable to the parent for 2024 is approximately 3.368 billion yuan, a year-on-year increase of 18.05%.
CHINARES PHARMA (03320) announced the 2024 performance of China Resources Sanjiu Medical & Pharmaceutical, with a total operating revenue of approximately 27.617 billion yuan, same...
Express News | China Resources Sanjiu Medical & Pharmaceutical: In 2024, Net income is expected to grow by 18.05% year-on-year, planning to distribute a cash dividend of 3.2 yuan for every 10 shares to all Shareholders.
